Remix Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Forge Rd Ste 400, Watertown, Massach...Phone Number
(781) 827-0901Website
www.remixtx.comRevenue
$13.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Remix Therapeutics
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression. Our innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin.Explore more
Remix Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Remix Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Remix Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Remix Therapeutics is spiking on competitors!
Earning: See what the market has to say on Remix Therapeutics recently announced quarterly report
Remix Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Remix Therapeutics
Click to see if Remix Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Remix Therapeutics has new funding data
Product Launch: Get notified when Remix Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Remix Therapeutics
Find 2 more new buyers
Compare Similar Companies to Remix Therapeutics
Compare insights from companies similar to Remix Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Remix Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Remix Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Remix Therapeutics.
Remix Therapeutics financials insights
Gather financial insights about Remix Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$81M
2022
Series B
$70M
2024
Other Financing Round
$60M
Remix Therapeutics Tech Stack
A closer look at the technologies used by Remix Therapeutics
Most Recent Scoops
Open Position
Open Position
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Remix Therapeutics News & Media
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their originRemix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety ProfileRemix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic CarcinomaRemix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Remix Therapeutics
Sign Up For FreeTo access detailed company insights
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Our REMaster technology platform allows us to identify patterns in RNA processing and exploit them to modulate gene expression. Our innovative therapeutic approach has the ability to al... Read More
